Screener
Twist Bioscience Corporation TWST Impairment Charges
Discontinued — last reported Q4 '25
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Twist Bioscience Corporation’s 10-K, filed November 17, 2025.
- Filed
- Nov 17, 2025
- Fiscal year
- FY2025
- Accession
- 0001581280-25-000025
| (In thousands, except per share data) | Year ended September 30, 2025 | Year ended September 30, 2024 | Year ended September 30, 2023 |
|---|---|---|---|
| Selling, general and administrative expenses | 246,976 | 218,398 | 189,738 |
| Restructuring and other costs | — | — | 9,384 |
| Change in fair value of contingent considerations and holdbacks | — | — | (5,913) |
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
| Gain on sale of business | 48,847 | — | — |
| Interest income | 11,364 | 15,344 | 14,365 |
Item 8. tatements and
FAQ
- What is Twist Bioscience Corporation's impairment charges?
- Twist Bioscience Corporation (TWST) reported impairment charges of $0 in Q3 2025.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about Twist Bioscience Corporation's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude